{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-22-276424","form_type":"8-K","ticker":"MDGL","cik":"0001157601","company_name":"MADRIGAL PHARMACEUTICALS, INC.","filed_at":"2022-11-03T23:59:59+00:00","discovered_at":"2026-05-14T18:03:49.760658+00:00","generated_at":"2026-06-22T08:03:59.140110+00:00","sec_items":["2.02","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Madrigal Q3 cash $153.2M; MAESTRO-NASH topline data on track for Q4 2022","bullets":["Cash, equivalents and marketable securities $153.2M at Sep 30, 2022, down from $270.3M at Dec 31, 2021.","R&D expenses $68.3M for Q3 2022 vs $54.9M in Q3 2021; G&A $12.1M vs $8.3M.","Cash used in operations for nine months ended Sep 30, 2022 was $166.3M.","Topline data from Phase 3 MAESTRO-NASH biopsy study expected in Q4 2022; NDA filing planned H1 2023.","Two resmetirom oral abstracts accepted at AASLD Liver Meeting presenting cirrhosis and noninvasive data."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-22-276424","json":"https://secwatch.observer/filing/0001193125-22-276424.json","markdown":"https://secwatch.observer/filing/0001193125-22-276424.md","text":"https://secwatch.observer/filing/0001193125-22-276424.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1157601/000119312522276424/0001193125-22-276424-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1157601/000119312522276424/d409333d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-22T08:03:59.140110+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}